Partial Epilepsy Treatment Adjunct — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for partial epilepsy treatment adjunct. 37 active patents protecting 2 drugs from 2+ originators. First major cliff: 2027. Daily refresh.

2
Approved drugs
37
Active US patents
65/100
Avg vulnerability
—
Annual revenue covered

Originators in Partial Epilepsy Treatment Adjunct

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Generic (originally UCB Pharma) 28 patents UCB 9 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating partial epilepsy treatment adjunct. Each bar = one year. Y-axis scaled to peak year (12 patents).

6
27
2
28
8
31
12
34
9
40

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Keppra
levetiracetam
 Generic (originally UCB Pharma) 28 56 — 2027-09-03
Vimpat
lacosamide
 UCB 9 73 — 2040-06-05

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
11883374 Vimpat method of use 75 2040-06-05
12042474 Vimpat method of use 75 2040-06-05
12042474 Vimpat method of use 75 2040-06-05
11883374 Vimpat method of use 75 2040-06-05
11883374 Vimpat method of use 75 2040-06-05
12042474 Vimpat method of use 75 2040-06-05
11337943 Vimpat method of use 70 2040-06-05
11337943 Vimpat method of use 70 2040-06-05
11337943 Vimpat method of use 70 2040-06-05
8802142 Keppra other 68 2031-12-07

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
11160786 Keppra formulation 42 2034-03-14
11160786 Keppra formulation 42 2034-03-14
11160786 Keppra formulation 42 2034-03-14
11160786 Keppra formulation 42 2034-03-14
8802142 Keppra formulation 53 2031-06-07
8802142 Keppra formulation 53 2031-06-07
8802142 Keppra formulation 53 2031-06-07
8802142 Keppra formulation 53 2031-06-07
8470367 Keppra formulation 55 2027-10-31
8431156 Keppra formulation 55 2027-10-31

Related